Evidence map›Paper›PMID 22414903›Full record

ArticleThe Pediatric infectious disease journal2012

Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.

Kevin M Watt, Michael Cohen-Wolkowiez, Robert M Ward, Daniel K Benjamin

Abstract readComment
In one paragraph

Article in The Pediatric infectious disease journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A Practical Guide to Antifungal Susceptibility Testing.Journal of the Pediatric Infectious Diseases Society · 2023
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Kevin M Watt
Michael Cohen-Wolkowiez
Robert M Ward
Daniel K Benjamin

Funding

Duke Research Training Program for PediatriciansT32HD043029 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2002 to 2017
$3.7M
Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental OutcomesR01HD057956 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2008 to 2012
$2.8M
Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental OutcomesR01FD003519 · FDA · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2008 to 2011
$1.6M
Mentorship of early-career pediatricians in quantitiative methods and therapeuticK24HD058735 · NICHD · DUKE UNIVERSITY · PI BENJAMIN, DANIEL K. · 2009 to 2018
$1.5M
Pharmacokinetics and Pharmacodynamics of Antibiotics in Premature InfantsK23HD064814 · NICHD · DUKE UNIVERSITY · PI COHEN-WOLKOWIEZ, MICHAEL · 2010 to 2013
$474k
FDA HHS 1R01FD003519-01FDA HHS R01 FD003519NICHD NIH HHS 1K23HD064814-01NICHD NIH HHS 1K24HD058735-01NICHD NIH HHS 1R01HD057956-02NICHD NIH HHS 5T32HD043029-09NICHD NIH HHS HHSN275201000002CNICHD NIH HHS K23 HD064814NICHD NIH HHS K24 HD058735NICHD NIH HHS R01 HD057956NICHD NIH HHS T32 HD043029
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antifungal AgentsCandidemiaCandidiasis, InvasiveEchinocandinsFemaleHumansLipopeptidesMaleMicafunginAntifungal AgentsEchinocandinsLipopeptidesMicafungin

Identifiers

PMID22414903
PMCPMC3356443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.